Placebo News and Research

RSS

Viking submits IND application to FDA to conduct VK2809 Phase 2 study in patients with LDL-C and fatty liver disease

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders, today announced that it has submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration to conduct a Phase 2 study of VK2809 in patients with hypercholesterolemia and fatty liver disease.

17 Nov 2015

First patient enrolled in Phase 2 clinical trial of Immune's bertilimumab in Ulcerative Colitis

Immune Pharmaceuticals Inc. announced today that the first patient has been enrolled into the Phase 2 clinical trial evaluating the safety and efficacy of its first in class fully human monoclonal antibody, bertilimumab in Ulcerative Colitis (UC).

17 Nov 2015

Haemodynamic variables may distinguish pre- from post-capillary PH

Researchers have identified the haemodynamic variables that best distinguish between patients with idiopathic pulmonary arterial hypertension and isolated post-capillary pulmonary hypertension.

16 Nov 2015

Angina in women linked with abnormal heart blood flow

Chest pain in female-pattern heart disease is linked with abnormal heart blood flow, demonstrated with a drug commonly used to alleviate chest pain patients with coronary artery disease, which was found to be ineffective in patients with moderate female-pattern heart disease, but may offer some relief for sicker patients, a new Cedars-Sinai Heart Institute study shows.

12 Nov 2015

OCD patients can benefit from exposure and response prevention therapy when drug treatment options fail

Patients with Obsessive-Compulsive Disorder (OCD) can improve their symptoms significantly by adding exposure and response prevention therapy to their treatment regimen when common drug treatment options have failed, according to new research from psychiatrists at the Perelman School of Medicine at the University of Pennsylvania.

12 Nov 2015

Tocilizumab drug offers potential treatment for patients with polymyalgia rheumatics

A drug approved to treat rheumatoid arthritis, tocilizumab (Actemra, Genentech), is a potential new therapy for patients with polymyalgia rheumatica, according to an open-label, phase II study presented at the annual meeting of the American College of Rheumatology/Association of Rheumatology Health Professionals on November 10.

11 Nov 2015

Study shows mindfulness meditation reduces pain more effectively than placebo

Scientists at Wake Forest Baptist Medical Center have found new evidence that mindfulness meditation reduces pain more effectively than placebo.

11 Nov 2015

Mallinckrodt Study Shows Acthar® Reduces Disease Activity in Patients with Persistently Active Systemic Lupus Erythematosus

Data presented yesterday by researchers for Mallinckrodt plc, a leading specialty biopharmaceutical company, suggest that H.P. Acthar® Gel (repository corticotropin injection) reduces certain measures of disease activity in patients with persistently active Systemic Lupus Erythematosus (SLE) who are receiving corticosteroid therapy.

10 Nov 2015

Cotellic (cobimetinib) approved to be used in combination with vemurafenib for melanoma treatment

The U.S. Food and Drug Administration today approved Cotellic (cobimetinib) to be used in combination with vemurafenib to treat advanced melanoma that has spread to other parts of the body or can't be removed by surgery, and that has a certain type of abnormal gene (BRAF V600E or V600K mutation).

10 Nov 2015

Drinking one 16-ounce energy drink may increase risk of cardiovascular events in young adults

New research shows that drinking one 16-ounce energy drink can increase blood pressure and stress hormone responses significantly. This raises the concern that these response changes could increase the risk of cardiovascular events, according to a study presented today at the American Heart Association's Scientific Sessions 2015.

10 Nov 2015

Idera begins enrollment in IMO-8400 Phase 2 clinical trial for treatment of dermatomyositis

Idera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing Toll-like receptor (TLR) and RNA therapeutics for patients with cancer and rare diseases, today announced that the company has commenced enrollment in a Phase 2 clinical trial of IMO-8400, an investigational TLR 7, 8 and 9 antagonist, in patients with dermatomyositis. Dermatomyositis is a rare and debilitating inflammatory muscle and skin disease associated with significant morbidity, decreased quality of life and an increased risk of premature death.

10 Nov 2015

Isosorbide mononitrate does not increase HFpEF patients' daily activity level

Heart failure patients with preserved ejection fraction (HFpEF) -- where the heart becomes stiff and cannot relax or fill properly -- did not have increased exercise tolerance after taking isosorbide mononitrate, compared to a placebo, according to a study presented today at the American Heart Association's Scientific Sessions 2015.

10 Nov 2015

Sorafenib increases progression-free survival and disease control rate in NSCLC patients

Sorafenib, a tyrosine kinase inhibitor (TKI) targeting the receptors for vascular endothelial growth factor, platelet derived growth factor, and mast/stem cell growth factor, modestly increases progression-free survival (PFS), time to progression, and disease control rate in non-small cell lung cancer (NSCLC) patients who have relapsed or failed two or three previous treatment regimens.

10 Nov 2015

Type 2 diabetes drug significantly reduces hospitalizations, death from heart failure

For the first time, research shows that a type 2 diabetes drug significantly reduces hospitalizations and death from heart failure.

10 Nov 2015

New review finds scant scientific evidence supporting use of cannabinoids in rheumatic diseases

Although there are anecdotal reports indicating that cannabinoids, especially marijuana (or herbal cannabis), may be of therapeutic benefit for some patients with rheumatic complaints, a new review published in Arthritis Care & Research, a journal of the American College of Rheumatology, finds scant scientific evidence supporting any use of cannabinoids in rheumatic diseases. Furthermore, not a single controlled study has examined herbal cannabis in the rheumatology patient population.

10 Nov 2015

Armaron Bio starts Phase 2 trial for novel lead candidate drug for heart failure

Armaron Bio, a Melbourne-based drug development company focused on heart failure and other diseases, is pleased to announce that it has begun its Phase II clinical trial for NP202, its novel lead candidate drug for heart failure.

9 Nov 2015

Medication not psychotherapy intensity sways treatment outcome in adult ADHD

Psychological interventions for adult attention deficit/hyperactivity disorder are best combined with methylphenidate, show findings from the COMPAS trial.

9 Nov 2015

Energy drink consumption linked with serious cardiovascular events

Anna Svatikova, M.D., Ph.D., of the Mayo Clinic, Rochester, Minn., and colleagues randomly assigned 25 healthy volunteers (age 18 years or older) to consume a can (480 mL; 16 fl. oz.) of a commercially available energy drink (Rockstar; Rockstar Inc) and placebo drink within 5 minutes, in random order on 2 separate days, maximum 2 weeks apart.

9 Nov 2015

Diabetes drug liraglutide ineffective in patients with advanced heart failure

In an attempt to correct defects in the energy generation that contributes to poor pump function among heart failure patients, researchers examined whether the diabetes drug liraglutide, could improve the condition of patients with advanced heart failure. Despite improvements in blood sugar control, the therapy did not improve the clinical stability or pumping action of the heart in patients with advanced heart failure.

9 Nov 2015

$Ixazomib’s phase 3 study in relapsed/refractory multiple myeloma presented$

Ixazomib’s phase 3 study in relapsed/refractory multiple myeloma presented

Takeda Pharmaceutical Company Limited today announced that it will present Phase 3 data from the TOURMALINE-MM1 ixazomib clinical trial at the 57th American Society of Hematology (ASH) Annual Meeting to be held in Orlando, Florida from December 5 to 8, 2015.

6 Nov 2015

Placebo News and Research

Viking submits IND application to FDA to conduct VK2809 Phase 2 study in patients with LDL-C and fatty liver disease

First patient enrolled in Phase 2 clinical trial of Immune's bertilimumab in Ulcerative Colitis

Haemodynamic variables may distinguish pre- from post-capillary PH

Angina in women linked with abnormal heart blood flow

OCD patients can benefit from exposure and response prevention therapy when drug treatment options fail

Tocilizumab drug offers potential treatment for patients with polymyalgia rheumatics

Study shows mindfulness meditation reduces pain more effectively than placebo

Mallinckrodt Study Shows Acthar® Reduces Disease Activity in Patients with Persistently Active Systemic Lupus Erythematosus

Cotellic (cobimetinib) approved to be used in combination with vemurafenib for melanoma treatment

Drinking one 16-ounce energy drink may increase risk of cardiovascular events in young adults

Idera begins enrollment in IMO-8400 Phase 2 clinical trial for treatment of dermatomyositis

Isosorbide mononitrate does not increase HFpEF patients' daily activity level

Sorafenib increases progression-free survival and disease control rate in NSCLC patients

Type 2 diabetes drug significantly reduces hospitalizations, death from heart failure

New review finds scant scientific evidence supporting use of cannabinoids in rheumatic diseases

Armaron Bio starts Phase 2 trial for novel lead candidate drug for heart failure

Medication not psychotherapy intensity sways treatment outcome in adult ADHD

Energy drink consumption linked with serious cardiovascular events

Diabetes drug liraglutide ineffective in patients with advanced heart failure

Ixazomib’s phase 3 study in relapsed/refractory multiple myeloma presented

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News